Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share (Tables)

v3.21.1
Net Loss Per Share (Tables)
3 Months Ended
Mar. 31, 2021
Net Loss Per Share  
Schedule of reconciliation of net loss

 

 

 

 

 

 

 

 

 

For the Three Months Ended

 

 

March 31,

 

    

2021

    

2020

Net loss

 

$

(7,623,140)

 

$

(6,373,420)

Net loss - Non-controlling interest

 

 

(90,962)

 

 

(81,314)

Net loss attributable to Heat Biologics, Inc.

 

$

(7,532,178)

 

$

(6,292,106)

 

 

 

 

 

 

 

Weighted-average common shares outstanding, basic and diluted

 

 

24,199,916

 

 

8,183,154

Net loss per share, basic and diluted

 

$

(0.31)

 

$

(0.77)

 

Schedule of potentially dilutive securities

 

 

 

 

 

 

    

2021

    

2020

Outstanding stock options

 

1,697,910

 

799,288

Restricted stock subject to forfeiture and restricted stock units

 

259,874

 

289,321

Outstanding common stock warrants

 

747,383

 

825,581